MaxCyte, Inc. Accounts Receivable
MaxCyte, Inc. (MXCT) had Accounts Receivable of $3.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Accounts Receivable, after Allowance for Credit Loss, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $3.92M.
- 2026-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $4.25M.
- 2025-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $3.50M.
- 2025-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $8.31M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current | Accounts Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.92M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $4.25M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $3.50M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $8.31M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $5.75M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $5.53M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $4.68M 10-K · filed 2026-03-25 | |
| 2024-09-30 | $4.56M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $4.58M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $5.99M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $5.78M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $8.17M 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $7.61M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $8.29M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $11.18M 10-K · filed 2024-03-12 | $11.65M 10-K · filed 2023-03-15 |
| 2022-09-30 | $7.43M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $7.43M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $8.63M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $6.88M 10-K · filed 2023-03-15 | |
| 2021-09-30 | $5.96M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $5.72M 10-Q · filed 2021-09-13 | |
| 2020-12-31 | $5.17M 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |